Review of the Efficacy and Safety of Cannabidiol with a Focus on
Children and Adolescents in the Treatment of Psychiatric
Symptoms and Disorders

Amanda   Yuan   Sun; Aimee      Sullivan; Jarrod   M   Leffler; Christopher   J   Hammond; Leslie      Hulvershorn; Leslie      Miller
doi:10.2174/2210676613666230901143229
Abstract

Cannabidiol (CBD) is a plant-derived cannabinoid found in cannabis and hemp plants with broad psychopharmacologic effects and poorly understood mechanisms of action that may include antioxidant and anti-inflammatory properties and central nervous system (CNS) modulation of endocannabinoid, glutamatergic, and serotonergic neurotransmission. This article reviews existing data on the safety and efficacy of CBD for mental and physical health indications in the pediatric population and for psychiatric disorders in adults, with a focus on clinical trials. Searches of PubMed and PsycINFO for articles through October 2021 focused on clinical trials on “cannabidiol” and “seizure” or “psychiatry” in youth and adults, identifying 686 articles that were then screened and evaluated for relevance. Research into the safety and efficacy of CBD led to the United States Food and Drug Administration's approval of Epidolex, a purified pharmaceuticalgrade CBD medicine, for treating drug-resistant seizures in Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex. Beyond treatment for rare seizure disorders, CBD has received growing public interest in recent years as a “natural” treatment for various other medical and psychiatric conditions, resulting in a rapidly expanding multi-billion-dollar US market for CBD dietary/health supplements and a growing number of Americans reporting regular use. However, the growing demand and broad claims of purported benefits have greatly outpaced the body of literature substantiating its use. Further, limited safety data in pediatric populations, drug-to-drug interactions between CBD and prescribed medications, and issues related to mislabeling and contamination have blunted enthusiasm for CBD in the pediatric healthcare community and indicate a need for additional research.
« Previous Next »
[]
Aran, A.; Cassuto, H.; Lubotzky, A.; Wattad, N.; Hazan, E. (2019), Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral Problems—A retrospective feasibility study. J. Autism Dev. Disord.,  49(3), 1284-1288.
 [http://dx.doi.org/10.1007/s10803-018-3808-2] [PMID: 30382443]

[]
Aran, A.; Harel, M.; Cassuto, H.; Polyansky, L.; Schnapp, A.; Wattad, N.; Shmueli, D.; Golan, D.; Castellanos, F.X. (2021), Cannabinoid treatment for autism: A proof-of-concept randomized trial. Mol. Autism,  12(1), 6.
 [http://dx.doi.org/10.1186/s13229-021-00420-2] [PMID: 33536055]

[]
Arkell, T.R.; Lintzeris, N.; Kevin, R.C.; Ramaekers, J.G.; Vandrey, R.; Irwin, C.; Mcgregor, I.S. (2019), Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology,  236(9), 2713-2724.
 [http://dx.doi.org/10.1007/s00213-019-05246-8]

[]
Arkell, T.R.; Vinckenbosch, F.; Kevin, R.C.; Theunissen, E.L.; Mcgregor, I.S.; Ramaekers, J.G. (2020), Effect of cannabidiol and Δ9-tetrahydrocannabinol on driving performance American Medical Association (AMA). JAMA,  324(21), 2177-2186.
 [http://dx.doi.org/10.1001/jama.2020.21218]

[]
Atakan, Z. (2012), Cannabis, a complex plant: Different compounds and different effects on individuals. Ther. Adv. Psychopharmacol.,  2(6), 241-254.
 [http://dx.doi.org/10.1177/2045125312457586]

[]
Babalonis, S.; Haney, M.; Malcolm, R.J.; Lofwall, M.R.; Votaw, V.R.; Sparenborg, S.; Walsh, S.L. (2017), Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend.,  172, 9-13.
 [http://dx.doi.org/10.1016/j.drugalcdep.2016.11.030] [PMID: 28088032]

[]
Barchel, D.; Stolar, O.; De-Haan, T.; Ziv-Baran, T.; Saban, N.; Fuchs, D.O.; Berkovitch, M. (2019), Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities Frontiers Media SA. Front. Pharmacol.,  9, 1521.
 [http://dx.doi.org/10.3389/fphar.2018.01521]

[]
Bergamaschi, M.M.; Queiroz, R.H.C.; Chagas, M.H.N.; de Oliveira, D.C.G.; De Martinis, B.S.; Kapczinski, F.; Quevedo, J.; Roesler, R.; Schröder, N.; Nardi, A.E.; Martín-Santos, R.; Hallak, J.E.C.; Zuardi, A.W.; Crippa, J.A.S. (2011), Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology,  36(6), 1219-1226.
 [http://dx.doi.org/10.1038/npp.2011.6] [PMID: 21307846]

[]
Berger, M.; Li, E.; Rice, S.; Davey, C. G.; Ratheesh, A.; Adams, S.; Jackson, H.; Hetrick, S.; Parker, A.; Spelman, T.; Kevin, R.; McGregor, I. S.; McGorry, P.; Amminger, G. P. (2022), Cannabidiol for	treatment-resistant anxiety disorders in young people: An open-label trial. J Clin Psychiatry,  83(5), 21m14130.
 [http://dx.doi.org/10.4088/JCP.21m14130]

[]
Bhattacharyya, S.; Morrison, P.D.; Fusar-Poli, P.; Martin-Santos, R.; Borgwardt, S.; Winton-Brown, T.; Nosarti, C.; O’ Carroll, C.M.; Seal, M.; Allen, P.; Mehta, M.A.; Stone, J.M.; Tunstall, N.; Giampietro, V.; Kapur, S.; Murray, R.M.; Zuardi, A.W.; Crippa, J.A.; Atakan, Z.; McGuire, P.K. (2010), Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology,  35(3), 764-774.
 [http://dx.doi.org/10.1038/npp.2009.184] [PMID: 19924114]

[]
Black, N.; Stockings, E.; Campbell, G.; Tran, L.T.; Zagic, D.; Hall, W.D.; Farrell, M.; Degenhardt, L. (2019), Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry,  6(12), 995-1010.
 [http://dx.doi.org/10.1016/S2215-0366(19)30401-8] [PMID: 31672337]

[]
Boggs, D.L.; Surti, T.; Gupta, A.; Gupta, S.; Niciu, M.; Pittman, B.; Schnakenberg Martin, A.M.; Thurnauer, H.; Davies, A.; D’Souza, D.C.; Ranganathan, M. (2018), The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology ,  235(7), 1923-1932.
 [http://dx.doi.org/10.1007/s00213-018-4885-9] [PMID: 29619533]

[]
Bonn-Miller, M.O.; Loflin, M.J.E.; Thomas, B.F.; Marcu, J.P.; Hyke, T.; Vandrey, R. (2017), Labeling accuracy of cannabidiol extracts sold online. JAMA,  318(17), 1708-1709.
 [http://dx.doi.org/10.1001/jama.2017.11909] [PMID: 29114823]

[]
Chesney, E.; Oliver, D.; Green, A.; Sovi, S.; Wilson, J.; Englund, A.; Mcguire, P. (2020), Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology,  45(11), 1799-1806.
 [http://dx.doi.org/10.1038/s41386-020-0667-2]

[]
Devinsky, O.; Cross, J.H.; Laux, L.; Marsh, E.; Miller, I.; Nabbout, R.; Scheffer, I.E.; Thiele, E.A.; Wright, S. (2017), Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N. Engl. J. Med.,  376(21), 2011-2020.
 [http://dx.doi.org/10.1056/NEJMoa1611618] [PMID: 28538134]

[]
Devinsky, O.; Marsh, E.; Friedman, D.; Thiele, E.; Laux, L.; Sullivan, J.; Miller, I.; Flamini, R.; Wilfong, A.; Filloux, F.; Wong, M.; Tilton, N.; Bruno, P.; Bluvstein, J.; Hedlund, J.; Kamens, R.; Maclean, J.; Nangia, S.; Singhal, N.S.; Wilson, C.A.; Patel, A.; Cilio, M.R. (2016), Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol.,  15(3), 270-278.
 [http://dx.doi.org/10.1016/S1474-4422(15)00379-8] [PMID: 26724101]

[]
Devinsky, O.; Nabbout, R.; Miller, I.; Laux, L.; Zolnowska, M.; Wright, S.; Roberts, C. (2019), Long-term cannabidiol treatment in patients with dravet syndrome: An open-label extension trial. Epilepsia,  60(2), 294-302.
 [http://dx.doi.org/10.1111/epi.14628] [PMID: 30582156]

[]
Devinsky, O.; Patel, A.D.; Cross, J.H.; Villanueva, V.; Wirrell, E.C.; Privitera, M.; Greenwood, S.M.; Roberts, C.; Checketts, D.; VanLandingham, K.E.; Zuberi, S.M. 2(018a), Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N. Engl. J. Med.,  378(20), 1888-1897. a
 [http://dx.doi.org/10.1056/NEJMoa1714631] [PMID: 29768152]

[]
Devinsky, O.; Patel, A.D.; Thiele, E.A.; Wong, M.H.; Appleton, R.; Harden, C.L.; Greenwood, S.; Morrison, G.; Sommerville, K. 2(018b), Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology,  90(14), e1204-e1211. b
 [http://dx.doi.org/10.1212/WNL.0000000000005254] [PMID: 29540584]

[]
Efron, D.; Freeman, J.L.; Cranswick, N.N.; Payne, J.M.; Mulraney, M.; Prakash, C.; Williams, K. (2021), A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability Wiley. Br. J. Clin. Pharmacol.,  87(2), 436-446.
 [http://dx.doi.org/10.1111/bcp.14399]

[]
Fairhurst, C.; Kumar, R.R.; Checketts, D.D.; Tayo, B.; Turner, S. (2020), Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: A randomized controlled trial. Dev. Med. Child Neurol.,  62(9), 1031-1039.
 [http://dx.doi.org/10.1111/dmcn.14548]

[]
Fischer, A.S.; Tapert, S.F.; Louie, D.L.; Schatzberg, A.F.; Singh, M.K. (2020), Cannabis and the developing adolescent brain. Curr. Treat. Options Psychiatry,  7(2), 144-161.
 [http://dx.doi.org/10.1007/s40501-020-00202-2] [PMID: 32714742]

[]
Fleury-Teixeira, P.; Caixeta, F.V.; Ramires Da Silva, L.C.; Brasil-Neto, J.P.; Malcher-Lopes, R. (2019), Effects of CBD-enriched cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Front. Neurol.,  10, 1145.
 [http://dx.doi.org/10.3389/fneur.2019.01145]

[]
Food Business News. (2019). U.S. hemp acres more than	triple.  Available From: https://www.foodbusinessnews.net/articles/13224-us-hemp-acres-more-than-triple

[]
Freedman, D.A.; Patel, A.D. (2018), Inadequate regulation contributes to mislabeled online cannabidiol products. Pediatr. Neurol. Briefs,  32(0), 3.
 [http://dx.doi.org/10.15844/pedneurbriefs-32-3] [PMID: 30008541]

[]
Freeman, T.P.; Hindocha, C.; Baio, G.; Shaban, N.D.C.; Thomas, E.M.; Astbury, D.; Freeman, A.M.; Lees, R.; Craft, S.; Morrison, P.D.; Bloomfield, M.A.P.; O’Ryan, D.; Kinghorn, J.; Morgan, C.J.A.; Mofeez, A.; Curran, H.V. (2020), Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry,  7(10), 865-874.
 [http://dx.doi.org/10.1016/S2215-0366(20)30290-X] [PMID: 32735782]

[]
Gallup. (2019). 14% of americans say they use CBD	products.  Available From: https://news.gallup.com/ poll/263147/americans-say-cbd-products.aspx

[]
Gaston, T.E.; Bebin, E.M.; Cutter, G.R.; Liu, Y.; Szaflarski, J.P. (2017), Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia,  58(9), 1586-1592.
 [http://dx.doi.org/10.1111/epi.13852]

[]
Gill, L.L. (2019).CBD goes mainstream.,  Available From: https://www.consumerreports.org/cbd/cbd-goes-mainstream/

[]
Gilmartin, C.G.S.; Dowd, Z.; Parker, A.P.J.; Harijan, P. (2021), Interaction of cannabidiol with other antiseizure medications: A narrative review. Seizure,  86(189), 196.
 [http://dx.doi.org/10.1016/j.seizure.2020.09.010]

[]
Pharmaceuticals, G.W. (2021).Information on obtaining sativex.,  Available From: https://www.gwpharm.com/ healthcare-professionals/sativex/prescribing-information

[]
Hammond, C.J.; Chaney, A.; Hendrickson, B.; Sharma, P. (2020), Cannabis use among U.S. adolescents in the era of marijuana legalization: A review of changing use patterns, comorbidity, and health correlates. Int. Rev. Psychiatry,  32(3), 221-234.
 [http://dx.doi.org/10.1080/09540261.2020.1713056]

[]
Haney, M.; Malcolm, R.J.; Babalonis, S.; Nuzzo, P.A.; Cooper, Z.D.; Bedi, G.; Gray, K.M.; McRae-Clark, A.; Lofwall, M.R.; Sparenborg, S.; Walsh, S.L. (2016), Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology,  41(8), 1974-1982.
 [http://dx.doi.org/10.1038/npp.2015.367] [PMID: 26708108]

[]
Herbst, J.; Musgrave, G. (2020), Respiratory depression following an accidental overdose of a CBD-labeled product: A pediatric case report. J. Am. Pharm. Assoc.,  60(1), 248-252.
 [http://dx.doi.org/10.1016/j.japh.2019.09.023] [PMID: 31767538]

[]
Heussler, H.; Cohen, J.; Silove, N.; Tich, N.; Bonn-Miller, M.O.; Du, W.; Sebree, T. (2019), A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J. Neurodevelop Disord.,  11, 16.
 [http://dx.doi.org/10.1186/s11689-019-9277-x]

[]
Hill, K.P.; Gold, M.S.; Nemeroff, C.B.; McDonald, W.; Grzenda, A.; Widge, A.S. (2021), Risks and benefits of cannabis and cannabinoids in psychiatry. Am. J. Psychiatry,  179(2), 98-109.
 [http://dx.doi.org/10.1176/appi.ajp.2021.21030320] [PMID: 34875873]

[]
Horth, R.Z.; Crouch, B.; Horowitz, B.Z.; Prebish, A.; Slawson, M.M.; Mcnair, J.; Dunn, A. (2018), Notes from the field: Acute poisonings from a synthetic cannabinoid sold as cannabidiol — utah, 2017–2018. MMWR Morb. Mortal. Wkly. Rep.,  67(20), 587-588.
 [http://dx.doi.org/10.15585/mmwr.mm6720a5]

[]
Hundal, H.; Lister, R.; Evans, N.; Antley, A.; Englund, A.; Murray, R.M.; Freeman, D.; Morrison, P.D. (2018), The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J. Psychopharmacol.,  32(3), 276-282.
 [http://dx.doi.org/10.1177/0269881117737400] [PMID: 29086614]

[]
Hurd, Y.L.; Spriggs, S.; Alishayev, J.; Winkel, G.; Gurgov, K.; Kudrich, C.; Oprescu, A.M.; Salsitz, E. (2019), Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am. J. Psychiatry,  176(11), 911-922.
 [http://dx.doi.org/10.1176/appi.ajp.2019.18101191] [PMID: 31109198]

[]
Hussain, S.A.; Dlugos, D.J.; Cilio, M.R.; Parikh, N.; Oh, A.; Sankar, R. (2020), Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study. Epilepsy Behav.,  102, 106826.
 [http://dx.doi.org/10.1016/j.yebeh.2019.106826] [PMID: 31816477]

[]
Jazz Pharmaceuticals. , (2022). EPIDIOLEX ® (cannabidiol) oral solution;  Available From: https://pp.jazz pharma.com/pi/epidiolex.en.USPI.pdf

[]
Kayser, R.R.; Haney, M.; Raskin, M.; Arout, C.; Simpson, H.B. (2020), Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. Depress. Anxiety,  37(8), 801-811.
 [http://dx.doi.org/10.1002/da.23032]

[]
Klier, C.M.; Amminger, G.P.; Kothgassner, O.D.; Laczkovics, C.; Felnhofer, A. , (2021); 31, pp. Letter to the editor: Cannabidiol Treatment—Is there an effect on	cognitive functioning, quality of life, and behavior? A case report. In: J. Child Adolesc. Pharmacol; (6)447-449.
 [http://dx.doi.org/10.1089/cap.2020.0203]

[]
Klier, C.M.; de Gier, C.; Felnhofer, A.; Laczkovics, C.; Amminger, P.G. (2020), A case report of cannabidiol treatment of a crohn’s disease patient with anxiety disorder. J. Clin. Psychopharmacol.,  40(1), 90-92.
 [http://dx.doi.org/10.1097/JCP.0000000000001152] [PMID: 31834086]

[]
Kuhlen, M.; Hoell, J.I.; Gagnon, G.; Balzer, S.; Oommen, P.T.; Borkhardt, A.; Janßen, G. (2016), Effective treatment of spasticity using dronabinol in pediatric palliative care. Eur. J. Paediatr. Neurol.,  20(6), 898-903.
 [http://dx.doi.org/10.1016/j.ejpn.2016.07.021] [PMID: 27506815]

[]
Laczkovics, C.; Kothgassner, O.D.; Felnhofer, A.; Klier, C.M. (2021), Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Neuropsychiatrie,  35(1), 31-34.
 [http://dx.doi.org/10.1007/s40211-020-00334-0] [PMID: 32052321]

[]
Lagae, L. (2020), Long-term effects of cannabinoids on development/behaviour. Epileptic Disord.,  22(S1), 33-37.

[]
Leas, E.C.; Nobles, A.L.; Caputi, T.L.; Dredze, M.; Smith, D.M.; Ayers, J.W. (2019), Trends in internet searches for cannabidiol (CBD) in the United States. JAMA Netw. Open,  2(10), e1913853.
 [http://dx.doi.org/10.1001/jamanetworkopen.2019.13853] [PMID: 31642924]

[]
Leweke, F.M.; Rohleder, C.; Gerth, C.W.; Hellmich, M.; Pukrop, R.; Koethe, D. (2021), Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial. Front. Pharmacol.,  12, 614811.
 [http://dx.doi.org/10.3389/fphar.2021.614811] [PMID: 33995015]

[]
Libzon, S.; Schleider, L.B.L.; Saban, N.; Levit, L.; Tamari, Y.; Linder, I.; Lerman-Sagie, T.; Blumkin, L. (2018), Medical cannabis for pediatric moderate to severe complex motor disorders. J. Child Neurol.,  33(9), 565-571.
 [http://dx.doi.org/10.1177/0883073818773028] [PMID: 29766748]

[]
Linares, I.M.P.; Guimaraes, F.S.; Eckeli, A.; Crippa, A.C.S.; Zuardi, A.W.; Souza, J.D.S.; Crippa, J.A.S. (2018), No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: A randomized, double-blind, placebo-controlled, crossover study. Front. Pharmacol.,  9, 315.
 [http://dx.doi.org/10.3389/fphar.2018.00315]

[]
Lintzeris, N.; Bhardwaj, A.; Mills, L.; Dunlop, A.; Copeland, J.; McGregor, I.; Bruno, R.; Gugusheff, J.; Phung, N.; Montebello, M.; Chan, T.; Kirby, A.; Hall, M.; Jefferies, M.; Luksza, J.; Shanahan, M.; Kevin, R.; Allsop, D. (2019), Nabiximols for the treatment of cannabis dependence: A randomized clinical trial. JAMA Intern. Med.,  179(9), 1242-1253.
 [http://dx.doi.org/10.1001/jamainternmed.2019.1993] [PMID: 31305874]

[]
Lorenz, R. (2004), On the application of cannabis in paediatrics and epileptology. Neuroendocrinol. Lett.,  25(1-2), 40-44.
 [PMID: 15159680]

[]
Madden, K.; Tanco, K.; Bruera, E. (2020), Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics,  145(6), e20193256.
 [http://dx.doi.org/10.1542/peds.2019-3256] [PMID: 32444381]

[]
Masataka, N. (2019), Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders Frontiers Media SA. Front. Psychol.,  10, 2466.
 [http://dx.doi.org/10.3389/fpsyg.2019.02466]

[]
McGuire, P.; Robson, P.; Cubala, W.J.; Vasile, D.; Morrison, P.D.; Barron, R.; Taylor, A.; Wright, S. (2018), Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am. J. Psychiatry,  175(3), 225-231.
 [http://dx.doi.org/10.1176/appi.ajp.2017.17030325] [PMID: 29241357]

[]
Morgan, C.J.A.; Freeman, T.P.; Hindocha, C.; Schafer, G.; Gardner, C.; Curran, H.V. (2018), Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl. Psychiatry,  8(1), 181.
 [http://dx.doi.org/10.1038/s41398-018-0191-x]

[]
Morgan, C.J.A.; Das, R.K.; Joye, A.; Curran, H.V.; Kamboj, S.K. (2013), Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. Addict. Behav.,  38(9), 2433-2436.
 [http://dx.doi.org/10.1016/j.addbeh.2013.03.011] [PMID: 23685330]

[]
Palmieri, B.; Laurino, C.; Vadalà, M. (2017), Short-term efficacy of CBD-enriched hemp oil in girls with dysautonomic syndrome after human papillomavirus vaccination. Isr. Med. Assoc. J.,  19(2), 79-84.
 [PMID: 28457055]

[]
Patel, S.J.; Khan, S.; Hamid, P. (2020), The association between cannabis use and schizophrenia: Causative or curative? A systematic review. Cureus,  12(7), e9309.
 [http://dx.doi.org/10.7759/cureus.9309]

[]
Poisson, K.; Wong, M.; Lee, C.; Cilio, M.R. (2020), Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study. Eur. J. Paediatr. Neurol.,  25, 77-81.
 [http://dx.doi.org/10.1016/j.ejpn.2019.12.024] [PMID: 31926846]

[]
Rosenberg, E.C.; Louik, J.; Conway, E.; Devinsky, O.; Friedman, D. (2017), Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia,  58(8), e96-e100.
 [http://dx.doi.org/10.1111/epi.13815] [PMID: 28617940]

[]
Sands, T.T.; Rahdari, S.; Oldham, M.S.; Caminha Nunes, E.; Tilton, N.; Cilio, M.R. (2019), Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: Results from an expanded access program in the US. CNS Drugs,  33(1), 47-60.
 [http://dx.doi.org/10.1007/s40263-018-0589-2]

[]
Sarris, J.; Sinclair, J.; Karamacoska, D.; Davidson, M.; Firth, J. (2020), Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review Springer Science and Business Media LLC. BMC Psychiatry,  20(1), 24.
 [http://dx.doi.org/10.1186/s12888-019-2409-8]

[]
Schoedel, K.A.; Szeto, I.; Setnik, B.; Sellers, E.M.; Levy-Cooperman, N.; Mills, C.; Etges, T.; Sommerville, K. (2018), Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav.,  88, 162-171.
 [http://dx.doi.org/10.1016/j.yebeh.2018.07.027] [PMID: 30286443]

[]
Schoedel, K.A.; Chen, N.; Hilliard, A.; White, L.; Stott, C.; Russo, E.; Wright, S.; Guy, G.; Romach, M.K.; Sellers, E.M. (2011), A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum. Psychopharmacol.,  26(3), 224-236.
 [http://dx.doi.org/10.1002/hup.1196] [PMID: 21671456]

[]
Schonhofen, P.; Bristot, I.J.; Crippa, J.A.; Hallak, J.E.C.; Zuardi, A.W.; Parsons, R.B.; Klamt, F. (2018), Cannabinoid-based therapies and brain development: Potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs,  32(8), 697-712.
 [http://dx.doi.org/10.1007/s40263-018-0550-4]

[]
Shannon, S.; Opila-Lehman, J. (2016), Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report. Perm. J.,  20(4), 16-005.
 [http://dx.doi.org/10.7812/TPP/16-005] [PMID: 27768570]

[]
Sharma, P.; Holland, A.; Sheikh, T.; Novy, B.; Oesterle, T.; Platt, R.; Hammond, C.J. (2022), Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. PEC Innov.,  1, 100044.
 [http://dx.doi.org/10.1016/j.pecinn.2022.100044]

[]
Singer, L.; Tokish, H.; Park, F.; Campisi, C.; Milanaik, R.L. (2020), The cannabidiol conundrum: Potential benefits and risks of cannabidiol products for children. Curr. Opin. Pediatr.,  32(1), 198-205.
 [http://dx.doi.org/10.1097/MOP.0000000000000861]

[]
SingleCare. (2021).CBD statistics 2021.,  Available From: https://www.singlecare.com/blog/news/cbd-statistics/

[]
Singh, R.K.; Dillon, B.; Tatum, D.A.; Van Poppel, K.C.; Bonthius, D.J. (2020), Drug-drug interactions between cannabidiol and lithium.,  Child Neurol Open,  , 2329048X20947896.7
 [http://dx.doi.org/10.1177/2329048X20947896]

[]
Szaflarski, J.P.; Bebin, E.M.; Comi, A.M.; Patel, A.D.; Joshi, C.; Checketts, D.; Wechsler, R. (2018), Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia,  59(8), 1540-1548.
 [http://dx.doi.org/10.1111/epi.14477]

[]
Thiele, E.A.; Bebin, E.M.; Bhathal, H.; Jansen, F.E.; Kotulska, K.; Lawson, J.A.; Zolnowska, M. (2021), Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial. JAMA Neurol.,  78(3), 285-292.
 [http://dx.doi.org/10.1001/jamaneurol.2020.4607]

[]
Thiele, E.A.; Marsh, E.D.; French, J.A.; Mazurkiewicz-Beldzinska, M.; Benbadis, S.R.; Joshi, C.; Lyons, P.D.; Taylor, A.; Roberts, C.; Sommerville, K.; Gunning, B.; Gawlowicz, J.; Lisewski, P.; Mazurkiewicz Beldzinska, M.; Mitosek Szewczyk, K.; Steinborn, B.; Zolnowska, M.; Hughes, E.; McLellan, A.; Benbadis, S.; Ciliberto, M.; Clark, G.; Dlugos, D.; Filloux, F.; Flamini, R.; French, J.; Frost, M.; Haut, S.; Joshi, C.; Kapoor, S.; Kessler, S.; Laux, L.; Lyons, P.; Marsh, E.; Moore, D.; Morse, R.; Nagaraddi, V.; Rosenfeld, W.; Seltzer, L.; Shellhaas, R.; Sullivan, J.; Thiele, E.; Thio, L.L.; Wang, D.; Wilfong, A. (2018), Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet,  391(10125), 1085-1096.
 [http://dx.doi.org/10.1016/S0140-6736(18)30136-3] [PMID: 29395273]

[]
Thiele, E.; Marsh, E.; Mazurkiewicz-Beldzinska, M.; Halford, J.J.; Gunning, B.; Devinsky, O.; Checketts, D.; Roberts, C. (2019), Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia,  60(3), 419-428.
 [http://dx.doi.org/10.1111/epi.14670] [PMID: 30740695]

[]
Thompson, M.D.; Martin, R.C.; Grayson, L.P.; Ampah, S.B.; Cutter, G.; Szaflarski, J.P.; Bebin, E.M. (2020), Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy. Epilepsy Behav.,  111, 107299.
 [http://dx.doi.org/10.1016/j.yebeh.2020.107299] [PMID: 32759071]

[]
Trigo, J.M.; Lagzdins, D.; Rehm, J.; Selby, P.; Gamaleddin, I.; Fischer, B.; Barnes, A.J.; Huestis, M.A.; Le Foll, B. (2016), Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend.,  161, 298-306.
 [http://dx.doi.org/10.1016/j.drugalcdep.2016.02.020] [PMID: 26925704]

[]
Trigo, J.M.; Soliman, A.; Quilty, L.C.; Fischer, B.; Rehm, J.; Selby, P.; Le Foll, B. (2018), Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS One,  13(1), e0190768.
 [http://dx.doi.org/10.1371/journal.pone.0190768]

[]
United States Department of Agriculture Farm bill..  Available from: https://www.usda.gov/farmbill

[]
US, Food & Drug Administration.FDA approves first drug	comprised of an active ingredient derived from	marijuana to treat rare, severe forms of epilepsy.  Available From: https://www.fda.gov/news-events/ press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms

[]
US, Food & Drug Administration. FDA approves new	indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic	disease.  Available From: https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare

[]
US, Food & Drug Administration. FDA regulation of  cannabis and cannabis-derived products, including cannabidiol (CBD).  Available From: https:// www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd

[]
van Amsterdam, J.; Vervloet, J.; de Weert, G.; Buwalda, V.J.A.; Goudriaan, A.E.; van den Brink, W. (2018), Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. Harm Reduct. J.,  15(1), 47.
 [http://dx.doi.org/10.1186/s12954-018-0253-7] [PMID: 30236118]

[]
Wheless, J.W.; Dlugos, D.; Miller, I.; Oh, D.A.; Parikh, N.; Phillips, S.; Cilio, M.R. (2019), Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs,  33(6), 593-604.
 [http://dx.doi.org/10.1007/s40263-019-00624-4]

[]
White, C.M. (2019), A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J. Clin. Pharmacol.,  59(7), 923-934.
 [http://dx.doi.org/10.1002/jcph.1387]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/2210676613666230901143229	Print ISSN 2210-6766
Publisher Name Bentham Science Publisher	Online ISSN 2210-6774
Adolescent Psychiatry

Review of the Efficacy and Safety of Cannabidiol with a Focus on Children and Adolescents in the Treatment of Psychiatric Symptoms and Disorders

Abstract Play Pause

Related Journals

Related Books

Abstract
